Pericytes: a double-edged sword in cancer therapy.

Pericytes, which envelope the vascular endothelium throughout the body, are often targeted to promote vascular normalization and restore normal function of blood vessels in cancer treatment. The goals of pericyte-targeted therapy tend to promote proper vascular normalization of the tumor. Tumor vascular normalization prevents metastasis, increases tumor oxygenation (making radiation more effective in killing tumor cells), optimizes Starling forces to increase delivery of cancer cell-directed therapies (e.g., chemotherapy or targeted agents), increases the efficacy of focal therapies (e.g., surgery or radiation), and increases recognition by the host immune system. We review how approaches in pericyte-targeted therapy aim to reach a balance between pro-angiogenic and anti-angiogenic function (i.e., by targeting platelet-derived growth factor beta receptors, vascular endothelial growth factor receptors and Tie-2) for tumor vascular normalization.

[1]  Zainab N. Khan,et al.  Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway. , 2012, Cancer cell.

[2]  D. Bodurka,et al.  Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers. , 2006, Gynecologic oncology.

[3]  Jianhua Huang,et al.  A Role for VEGF as a Negative Regulator of Pericyte Function and Vessel Maturation , 2008, Nature.

[4]  Howard A. Fine,et al.  Phase I/II Study of Imatinib Mesylate for Recurrent Malignant Gliomas: North American Brain Tumor Consortium Study 99-08 , 2006, Clinical Cancer Research.

[5]  R. Jain Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Y. Bang,et al.  Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. , 2011, The New England journal of medicine.

[7]  Holger Gerhardt,et al.  Pericytes limit tumor cell metastasis. , 2006, The Journal of clinical investigation.

[8]  D. Hanahan,et al.  Functions of Paracrine PDGF Signaling in the Proangiogenic Tumor Stroma Revealed by Pharmacological Targeting , 2008, PLoS medicine.

[9]  D. Sargent,et al.  Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial , 2013, The Lancet.

[10]  L. Ellis,et al.  Overexpression of PDGF-BB decreases colorectal and pancreatic cancer growth by increasing tumor pericyte content. , 2007, The Journal of clinical investigation.

[11]  米永 吉邦 Absence of smooth muscle actin-positive pericyte coverage of tumor vessels correlates with hematogenous metastasis and prognosis of colorectal cancer patients , 2007 .

[12]  O. Stoeltzing,et al.  Targeting FGFR/PDGFR/VEGFR Impairs Tumor Growth, Angiogenesis, and Metastasis by Effects on Tumor Cells, Endothelial Cells, and Pericytes in Pancreatic Cancer , 2011, Molecular Cancer Therapeutics.

[13]  H. Dvorak,et al.  Heterogeneity of the Tumor Vasculature , 2010, Seminars in thrombosis and hemostasis.

[14]  U. Gatzemeier,et al.  Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  B. Sennino Two is better than one: Benefits of VEGF and PDGF inhibition in ovarian cancer , 2010, Cancer biology & therapy.

[16]  J. Bergh,et al.  Prognostic significance of stromal platelet-derived growth factor beta-receptor expression in human breast cancer. , 2009, The American journal of pathology.

[17]  D. Schadendorf,et al.  Host-derived angiopoietin-2 affects early stages of tumor development and vessel maturation but is dispensable for later stages of tumor growth. , 2009, Cancer research.

[18]  B. Teh,et al.  Complexity of tumor vasculature in clear cell renal cell carcinoma , 2009, Cancer.

[19]  Denis Lacombe,et al.  Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Hubing Shi,et al.  Pulmonary vascular destabilization in the premetastatic phase facilitates lung metastasis. , 2009, Cancer research.

[21]  R. Jain A new target for tumor therapy. , 2009, The New England journal of medicine.

[22]  P. Koumoutsakos,et al.  Tumorigenesis and Neoplastic Progression Contrasting Actions of Selective Inhibitors of Angiopoietin-1 and Angiopoietin-2 on the Normalization of Tumor Blood Vessels , 2009 .

[23]  R. Jain,et al.  Angiopoietin-2 Interferes with Anti-VEGFR2–Induced Vessel Normalization and Survival Benefit in Mice Bearing Gliomas , 2010, Clinical Cancer Research.

[24]  T. Sjöblom,et al.  Tumors and an Associated Increase in Tumor Growth Rate Melanoma Cells Leads to Increased Pericyte Abundance in Platelet-Derived Growth Factor Production by B 16 Updated , 2004 .

[25]  M. Skobe,et al.  Platelet-derived growth factor-B normalizes micromorphology and vessel function in vascular endothelial growth factor-A-induced squamous cell carcinomas. , 2010, The American journal of pathology.

[26]  Kristian Pietras,et al.  A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  W. Hong,et al.  Phase II Trials of Imatinib Mesylate and Docetaxel in Patients with Metastatic Non-small Cell Lung Cancer and Head and Neck Squamous Cell Carcinoma , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[28]  Xin Huang,et al.  Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial , 2006, The Lancet.

[29]  P. Stattin,et al.  Stromal PDGFRβ Expression in Prostate Tumors and Non-Malignant Prostate Tissue Predicts Prostate Cancer Survival , 2010, PloS one.

[30]  C. Grommes,et al.  Bevacizumab for the treatment of high-grade glioma: an update after Phase III trials , 2014, Expert opinion on biological therapy.

[31]  K. Jennbacken,et al.  Pericyte coverage decreases invasion of tumour cells into blood vessels in prostate cancer xenografts , 2009, Prostate Cancer and Prostatic Diseases.

[32]  G. Bodoky,et al.  Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). , 2010, The oncologist.

[33]  David J. Mooney,et al.  Spatio–temporal VEGF and PDGF Delivery Patterns Blood Vessel Formation and Maturation , 2007, Pharmaceutical Research.

[34]  G. Abou-Alfa,et al.  Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. , 2010, JAMA.

[35]  M. Merchant,et al.  Therapeutic angiogenesis due to balanced single‐vector delivery of VEGF and PDGF‐BB , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[36]  C. Heldin,et al.  Combined Anti-Angiogenic Therapy Targeting PDGF and VEGF Receptors Lowers the Interstitial Fluid Pressure in a Murine Experimental Carcinoma , 2009, PloS one.

[37]  J. Leonard,et al.  Imatinib disrupts lymphoma angiogenesis by targeting vascular pericytes. , 2013, Blood.

[38]  Liz Y. Han,et al.  Dual Targeting of Endothelial Cells and Pericytes in Antivascular Therapy for Ovarian Carcinoma , 2007, Clinical Cancer Research.

[39]  C. Kuo,et al.  Soluble receptor-mediated selective inhibition of VEGFR and PDGFRβ signaling during physiologic and tumor angiogenesis , 2008, Proceedings of the National Academy of Sciences.

[40]  Shaun O'Brien,et al.  Pericyte requirement for anti-leak action of angiopoietin-1 and vascular remodeling in sustained inflammation. , 2011, The American journal of pathology.

[41]  Gabriele Bergers,et al.  Modes of resistance to anti-angiogenic therapy , 2008, Nature Reviews Cancer.

[42]  H. Augustin,et al.  Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. , 2000, Cancer research.

[43]  K. Alitalo,et al.  Vascular Endothelial Growth Factor-A and Platelet-Derived Growth Factor-B Combination Gene Therapy Prolongs Angiogenic Effects via Recruitment of Interstitial Mononuclear Cells and Paracrine Effects Rather Than Improved Pericyte Coverage of Angiogenic Vessels , 2008, Circulation research.

[44]  D. McDonald,et al.  Rapid vascular regrowth in tumors after reversal of VEGF inhibition. , 2006, The Journal of clinical investigation.